Abstract:Objective: To verify the cytopathological Bethesda System classification of thyroid nodule fine-needle aspiration biopsy (FNAB) in MTC patients and to assess the role of preoperative serum calcitonin (CT) levels in the investigation of this neoplasm in medullary thyroid cancer (MTC) patients under observation at the Uopeccan (União Oeste Paranaense de Estudos e Combate ao Câncer). Materials and methods: This is a cross-sectional review of medical records of patients monitored at the thyroid cancer outpatient c… Show more
“…Calcitonin measurement helped diagnosis in 1 of 427 cases with AUS/FLUS cytology, and indicated MTC in 2 of 73 cases with FN/SFN cytology. An indeterminate cytology result was found at the rate of 0-30% in the previous studies investigating the FNAB results of large medullary cancer case series, which was similar to the current case series [ 4 , 18 , 33 ]. While routine calcitonin measurement seems to be reasonable in cases with FN/SFN, in cases with multiple AUS cytology, instead of routine calcitonin measurement, calcitonin can be screened particularly in patients with suspicious features of MTC on ultrasonography or with a family history of MTC [ 6 ].…”
Section: Discussionsupporting
confidence: 90%
“…Measurement of serum calcitonin is a sensitive and specific marker in the diagnosis and follow-up of MTC [ 13 , 15 ] and it is well known that the most important factor in MTC prognosis is early diagnosis of the disease [ 13 , 16 ]. Calcitonin measurement has been shown to be superior to FNAB in MTC detection in the previous studies [ 4 , 17 , 18 ] Nevertheless, routine calcitonin measurement in nodular thyroid disease is controversial. Although the detection of MTC through routine calcitonin screening has recently been shown to lead to early stage diagnosis, the ATA guideline did not make recommendations for routine calcitonin measurement in nodular thyroid patients, leaving the decision up to the clinicians [ 13 ].…”
Routine calcitonin measurement in patients with nodular thyroid disease is rather controversial. The aim of this study was to evaluate the contribution of serum calcitonin measurement in the diagnostic evaluation of thyroid nodules with insufficient, indeterminate, or suspicious cytology. Out of 1668 patients who underwent thyroidectomy with the diagnosis of nodular thyroid disease and were screened, 873 patients with insufficient, indeterminate, or suspicious fine needle aspiration biopsy results were included in the study. From the total number of patients in this study, 10 (1.1%) were diagnosed as medullary thyroid cancer (MTC) using histopathology. The calcitonin level was detected to be above the assay-specific cut-off in 23 (2.6%) patients ranging between 6.5 - 4450 pg/mL. While hypercalcitoninemia was detected in all 10 MTC patients, a false positive elevation of serum calcitonin was detected in 13 patients (1.5%). Of the MTC group, 7 patients had cytology results that were suspicious for malignancy (Bethesda V), one patient’s cytology showed atypia of undetermined significance (Bethesda III) and two patient’s cytology results were suspicious for follicular neoplasm (Bethesda IV). Among the cases with non-diagnostic cytology (Bethesda I), none of the patients were diagnosed with MTC. In conclusion, routine serum calcitonin measurement can be performed in selected cases rather than in all nodular thyroid patients. While it is reasonable to perform routine calcitonin measurement in patients with Bethesda IV and Bethesda V, this measurement was not useful in Bethesda I patients. In Bethesda III patients, patient-based decisions can be made according to their calcitonin measurement.
Read more in PDF.
“…Calcitonin measurement helped diagnosis in 1 of 427 cases with AUS/FLUS cytology, and indicated MTC in 2 of 73 cases with FN/SFN cytology. An indeterminate cytology result was found at the rate of 0-30% in the previous studies investigating the FNAB results of large medullary cancer case series, which was similar to the current case series [ 4 , 18 , 33 ]. While routine calcitonin measurement seems to be reasonable in cases with FN/SFN, in cases with multiple AUS cytology, instead of routine calcitonin measurement, calcitonin can be screened particularly in patients with suspicious features of MTC on ultrasonography or with a family history of MTC [ 6 ].…”
Section: Discussionsupporting
confidence: 90%
“…Measurement of serum calcitonin is a sensitive and specific marker in the diagnosis and follow-up of MTC [ 13 , 15 ] and it is well known that the most important factor in MTC prognosis is early diagnosis of the disease [ 13 , 16 ]. Calcitonin measurement has been shown to be superior to FNAB in MTC detection in the previous studies [ 4 , 17 , 18 ] Nevertheless, routine calcitonin measurement in nodular thyroid disease is controversial. Although the detection of MTC through routine calcitonin screening has recently been shown to lead to early stage diagnosis, the ATA guideline did not make recommendations for routine calcitonin measurement in nodular thyroid patients, leaving the decision up to the clinicians [ 13 ].…”
Routine calcitonin measurement in patients with nodular thyroid disease is rather controversial. The aim of this study was to evaluate the contribution of serum calcitonin measurement in the diagnostic evaluation of thyroid nodules with insufficient, indeterminate, or suspicious cytology. Out of 1668 patients who underwent thyroidectomy with the diagnosis of nodular thyroid disease and were screened, 873 patients with insufficient, indeterminate, or suspicious fine needle aspiration biopsy results were included in the study. From the total number of patients in this study, 10 (1.1%) were diagnosed as medullary thyroid cancer (MTC) using histopathology. The calcitonin level was detected to be above the assay-specific cut-off in 23 (2.6%) patients ranging between 6.5 - 4450 pg/mL. While hypercalcitoninemia was detected in all 10 MTC patients, a false positive elevation of serum calcitonin was detected in 13 patients (1.5%). Of the MTC group, 7 patients had cytology results that were suspicious for malignancy (Bethesda V), one patient’s cytology showed atypia of undetermined significance (Bethesda III) and two patient’s cytology results were suspicious for follicular neoplasm (Bethesda IV). Among the cases with non-diagnostic cytology (Bethesda I), none of the patients were diagnosed with MTC. In conclusion, routine serum calcitonin measurement can be performed in selected cases rather than in all nodular thyroid patients. While it is reasonable to perform routine calcitonin measurement in patients with Bethesda IV and Bethesda V, this measurement was not useful in Bethesda I patients. In Bethesda III patients, patient-based decisions can be made according to their calcitonin measurement.
Read more in PDF.
“…The 25 articles 19–43 found according to the criteria of the present systematic review were published between 2002 and 2021. The authors were from eastern countries in 18 papers, European in five, and American in two.…”
Objective
Ultrasound (US) is the pivotal procedure during the diagnostic work‐up of thyroid nodule and several US‐based risk stratification systems (RSSs) have been recently developed. Since the performance of RSSs in detecting medullary thyroid carcinoma (MTC) has been rarely investigated, the present systematic review aimed to achieve high evidence about (1) how MTC is classified according to RSSs; (2) if RSSs correctly classify MTC at high risk/suspicion, and (3) if MTC is classified as suspicious at US when RSSs are not used.
Design
The review was performed according to MOOSE. The online search was performed by specific algorithm on January 2022. A random‐effects model was used for statistical analysis.
Results
Twenty‐five papers were initially included and their risk of bias was generally low. According to ATA system, 65% of MTCs was assessed at high suspicion and 25% at intermediate suspicion. Considering all RSSs, a 54.8% of MTCs was put in a high‐risk/suspicion category. Pooling data from studies without data of RSS the prevalence of ultrasonographically suspicious MTCs was 60%.
Conclusions
As conclusion, MTC presentation according to RSSs is partially known and it is classified in a high‐risk/suspicion category of RSSs in just over a half of cases. This advises for further studies, ideally supported by international societies, to better define the US presentation of MTC.
“…Del Rio, Rico, Bordiu, & Novoa, 1987). Oliveira et al,( 2021) detected a reduction in calcitonin levels after thyroidectomy (Oliveira et al, 2021). Qu et al, (2022), (Tinawi, 2021) andCornelius, (2020) suggested that hypoalbuminemia may be the main factor in the pathogenesis of postoperative hypocalcemia, when only total calcium is measured.…”
The incidence of post-thyroidectomy hypocalcemia is high while the factors involved include age (> 50 years), type of operation, operative time, neck dissection, histology of the surgical specimen and vocal fold paralysis. Low ionic calcium concentrations are indicative of the presence of symptoms of hypocalcemia and the need for oral calcium. Progression to definitive hypoparathyroidism occurs only in patients with clinical manifestations of post-thyroidectomy hypocalcemia. In general, the problem with post-surgical hypoparathyroidism resides in the surgical procedure itself. The most common are related to neuronal hyperexcitability, which explains the paresthesias, cramps and numbness, which usually start in the perioral region and on the fingertips. Muscle spasms and muscle stiffness are also common. When severe, hypocalcemia can lead to life-threatening spastic tetany, laryngospasm, and seizures. The current manuscript aimed to present a review of the bibliography on thyroidectomy and negative impact of its complications on human health, mainly because of a higher risk for developing hypocalcemia. To achieve the study goal, this review covered most recent published articles from 2017 onward.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.